Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 44.5 to 38.2.
-
Busy address KBO
15 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
OMEGA PHARMA INNOVATION & DEVELOPMENT from Gent, company number BE0884084724, closed financial year 2025 with a result of € 11.4 million after tax. For that financial year OMEGA PHARMA INNOVATION & DEVELOPMENT recorded revenue of € 16.3 million and equity of € 240.2 million. Compared with financial year 2023, the result moved from € 9.7 million to € 11.4 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
€ 240.2 million
▲ 93% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 11.4 million
▲ 17% vs 2023
Profit after tax over the fiscal year.
€ 7,220
▲ € 5,441 vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 116.8 million.
People and assets in 2025
38.2
▼ 4.9 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 5.6 million
▼ 7% vs 2023
€ 147,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5.5 million
▼ 69% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 188 days on average.
€ 865,003
▼ 21% vs 2023
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2021 | 2022 | 2023 | 2025 | Change 2023 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 44,673,298 | € 49,139,158 | € 55,237,932 | € 16,348,779 | ▼ 70% |
| Profit after taxes | € -9,851,355 | € 1,988,571 | € 9,744,434 | € 11,369,901 | ▲ 17% |
| Equity | € 121,409,522 | € 123,398,094 | € 124,642,527 | € 240,227,970 | ▲ 93% |
| Total debts | € 20,516,987 | € 22,264,276 | € 28,117,055 | € 6,364,765 | ▼ 77% |
| Cash | € 1,779 | € 1,779 | € 1,779 | € 7,220 | ▲ € 5,441 |
| Retained profit | € -221,577,538 | € -219,588,967 | € 1,250,332 | € 116,835,775 | ▲ € 115.6 million |
| Dividend | € 0 | € 0 | € 8,500,000 | € 0 | ▼ 100% |
| Balance sheet total | € 141,926,510 | € 145,662,369 | € 152,759,583 | € 246,592,735 | ▲ 61% |
| Employees (FTE) | 46.7 | 44.5 | 43.1 | 38.2 | ▼ 4.9 |
Key figures of OMEGA PHARMA INNOVATION & DEVELOPMENT, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OMEGA PHARMA INNOVATION & DEVELOPMENT?
What happened at OMEGA PHARMA INNOVATION & DEVELOPMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jonas Dhaenens stepped down as director. NBB
- Sonia Hollies stepped down as director. NBB
- Magali Verbraeken stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 11.4 million (▲ 17% vs 2023). Source: NBB ↗
- Anja van Winsberghe stepped down as director. NBB
- Jonas Dhaenens became a director. NBB
- Sonia Hollies became a director. NBB
- Magali Verbraeken became a director. NBB
In short
From € 9.9 million loss in 2021 to € 11.4 million profit in 2025.
Paid € 874,819 in corporate taxes since 2021.
Best year ever: 2025, with € 11.4 million profit.
Paid out € 8.5 million in dividends to the owners in total.
Management
The shares are held by Perrigo Holding NV (100%). It owns 100% of Adriatic BST DOO itself.
Directors
According to the 2025 annual accounts
Magali Verbraeken
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Belgium, Perrigo Capital, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P., OMEGA PHARMA INTERNATIONAL
since 2023 · until 2029
Anja van Winsberghe
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Belgium, Perrigo Capital, Perrigo Holding, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P. +2 more
since 2021 · until 2026
Sonia Hollies
Director
Also active at: Perrigo Capital, Perrigo Europe Invest, OMEGA PHARMA INTERNATIONAL
since 2024 · until 2030
Jonas Dhaenens
Director
Also active at: OMEGA PHARMA TRADING, Perrigo Capital, Perrigo Holding, Perrigo Europe Invest, Oce-Bio, OMEGA PHARMA INTERNATIONAL
since 2026 · until 2032
Shareholders
100%
Participations
Adriatic BST DOO
100%
Establishments
Establishment units
Physical locations of this company
Gaston Crommenlaan 6 box 606
9050 Gent
Venecoweg 26
9810 Nazareth-De Pinte
Active since 9 October 2006
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 15 companies are registered at this address.
All companies at this address →OMEGA PHARMA TRADING same network
€ 538,596 revenue · 2025
Perrigo Belgium same network
€ 44.6 million revenue · 2025
Perrigo Capital same network
€ 2.2 million revenue · 2025
Perrigo Holding same network
€ 48.4 million revenue · 2025
Perrigo Europe Invest same network
+10 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0884.084.724
- VAT number
- BE 0884.084.724
- Registered office
- Gaston Crommenlaan 6 bus 606, 9050 Gent
- Names & denominations
- OMEGA PHARMA INNOVATION & DEVELOPMENT · OPID · INNOVATION & DEVELOPMENT
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 October 2006
- Peppol
- Active · Active since 8 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied